[go: up one dir, main page]

PE20221790A1 - Composiciones de proteina anti-vegf y metodos para producir la misma - Google Patents

Composiciones de proteina anti-vegf y metodos para producir la misma

Info

Publication number
PE20221790A1
PE20221790A1 PE2022001025A PE2022001025A PE20221790A1 PE 20221790 A1 PE20221790 A1 PE 20221790A1 PE 2022001025 A PE2022001025 A PE 2022001025A PE 2022001025 A PE2022001025 A PE 2022001025A PE 20221790 A1 PE20221790 A1 PE 20221790A1
Authority
PE
Peru
Prior art keywords
minitrap
aflibercept
fraction
methods
producing
Prior art date
Application number
PE2022001025A
Other languages
English (en)
Inventor
Andrew Tustian
Ankit Vartak
Thomas Daly
Erica Pyles
Nisha Palackal
Shunhai Wang
Ning Li
Matthew Franklin
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=76210828&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20221790(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of PE20221790A1 publication Critical patent/PE20221790A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0031—Serum-free culture media
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21004—Trypsin (3.4.21.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/80—Fraction collectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2529/00—Culture process characterised by the use of electromagnetic stimulation
    • C12N2529/10—Stimulation by light
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027—Liquid chromatography

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Vascular Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

Referida a composiciones de proteinas anti-VEGF y metodos para producir MiniTrampa de aflibercept, a partir de una recoleccion clarificada producida por una celula cultivada en un medio quimicamente definido (CDM). Dicho metodo comprende: (a) unir aflibercept de tal recoleccion clarificada a una primera cromatografia de captura, (b) eluir el aflibercept y someterlo a escision enzimatica para remover su dominio Fc y formar asi la MiniTrampa, (c) someter el contenido de (b) a una segunda cromatografia de captura y realizar uno o mas lavados, en donde la primera fraccion de flujo continuo contiene la Minitrampa y presenta un primer color amarillo marron intenso, (d) someter tal primera fraccion de flujo continuo a cromatografia de intercambio anionico (AEX), (e) lavar la columna de AEX y (f) recolectar la Minitrampa en una segunda fraccion de flujo continuo, la cual tiene un segundo color amarillo marron menos intenso
PE2022001025A 2019-12-06 2020-08-18 Composiciones de proteina anti-vegf y metodos para producir la misma PE20221790A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962944635P 2019-12-06 2019-12-06
US202063065012P 2020-08-13 2020-08-13
PCT/US2020/046842 WO2021112927A1 (en) 2019-12-06 2020-08-18 Anti-vegf protein compositions and methods for producing the same

Publications (1)

Publication Number Publication Date
PE20221790A1 true PE20221790A1 (es) 2022-11-25

Family

ID=76210828

Family Applications (6)

Application Number Title Priority Date Filing Date
PE2022001022A PE20221788A1 (es) 2019-12-06 2020-08-18 Composiciones de proteina anti-vegf y metodos para producir la misma
PE2022001025A PE20221790A1 (es) 2019-12-06 2020-08-18 Composiciones de proteina anti-vegf y metodos para producir la misma
PE2022001026A PE20221791A1 (es) 2019-12-06 2020-08-18 Composiciones de proteina anti-vegf y metodos para producir la misma
PE2022001020A PE20221770A1 (es) 2019-12-06 2020-08-18 Composiciones de proteina anti-vegf y metodos para producir la misma
PE2022001024A PE20221261A1 (es) 2019-12-06 2020-08-18 Composiciones de proteina anti-vegf y metodos para producir la misma
PE2022001023A PE20221789A1 (es) 2019-12-06 2020-08-18 Composiciones de proteina anti-vegf y metodos para producir la misma

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2022001022A PE20221788A1 (es) 2019-12-06 2020-08-18 Composiciones de proteina anti-vegf y metodos para producir la misma

Family Applications After (4)

Application Number Title Priority Date Filing Date
PE2022001026A PE20221791A1 (es) 2019-12-06 2020-08-18 Composiciones de proteina anti-vegf y metodos para producir la misma
PE2022001020A PE20221770A1 (es) 2019-12-06 2020-08-18 Composiciones de proteina anti-vegf y metodos para producir la misma
PE2022001024A PE20221261A1 (es) 2019-12-06 2020-08-18 Composiciones de proteina anti-vegf y metodos para producir la misma
PE2022001023A PE20221789A1 (es) 2019-12-06 2020-08-18 Composiciones de proteina anti-vegf y metodos para producir la misma

Country Status (19)

Country Link
US (37) US11053280B2 (es)
EP (11) EP4524147A3 (es)
JP (14) JP2022548197A (es)
KR (13) KR20230152810A (es)
CN (6) CN114423783A (es)
AU (14) AU2020397803C1 (es)
BR (2) BR112021025359A2 (es)
CA (4) CA3172625A1 (es)
CO (6) CO2021018181A2 (es)
IL (18) IL296864B2 (es)
MX (10) MX2022006760A (es)
MY (12) MY190624A (es)
NZ (6) NZ781136A (es)
PE (6) PE20221788A1 (es)
SG (6) SG11202110968VA (es)
TW (10) TW202128743A (es)
UA (1) UA129709C2 (es)
WO (7) WO2021112928A1 (es)
ZA (5) ZA202107646B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210021299A (ko) 2018-05-10 2021-02-25 리제너론 파아마슈티컬스, 인크. 고농도 vegf 수용체 융합 단백질 함유 제제
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
AU2020208360B2 (en) * 2019-01-16 2025-05-08 Regeneron Pharmaceuticals, Inc. Method and system of identifying and quantifying antibody fragmentation
GB201910697D0 (en) * 2019-07-26 2019-09-11 Binding Site Group Ltd Lonisation control
KR20230152810A (ko) * 2019-12-06 2023-11-03 리제너론 파아마슈티컬스, 인크. 항-vegf 단백질 조성물 및 이를 생산하는 방법
JP2023525034A (ja) 2020-05-08 2023-06-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｖｅｇｆトラップおよびミニトラップならびに眼障害およびがんの治療方法
WO2022234412A1 (en) 2021-05-03 2022-11-10 Lupin Limited A process for purification of fc-fusion proteins
WO2023230486A2 (en) * 2022-05-23 2023-11-30 Inhalon Biopharma, Inc. Compositions and methods for inhalable therapeutics
TW202326138A (zh) * 2021-09-08 2023-07-01 美商再生元醫藥公司 用於定量抗體及其他含Ｆｃ蛋白之高通量及基於質譜之方法
AU2022358612A1 (en) * 2021-09-28 2024-04-11 Kashiv Biosciences, Llc An improved process of purification of fusion protein
CN116162148B (zh) * 2021-11-24 2025-09-09 中山光度生物医药有限公司 多特异性配体结合分子及其应用
WO2023137143A1 (en) * 2022-01-14 2023-07-20 Shattuck Labs, Inc. Methods of contaminant removal from protein isolates
AU2023404729A1 (en) * 2022-12-01 2025-06-26 Innovent Biologics (Suzhou) Co., Ltd. Trispecific fusion protein and use thereof
EP4646476A1 (en) * 2023-01-06 2025-11-12 Seismic Therapeutic, Inc. Protease variants and uses thereof
KR20240115650A (ko) 2023-01-19 2024-07-26 주식회사 스카이테라퓨틱스 티로신 키나아제 억제제의 무정형 나노 분자회합체와 이를 포함하는 조성물 및 그의 제조방법
WO2024206953A2 (en) * 2023-03-29 2024-10-03 Taktos Therapeutics Inc. Ides variant proteins and methods of using the same
WO2025030053A1 (en) * 2023-08-01 2025-02-06 Insmed Incorporated Novel igg proteases and methods of use thereof
WO2025227916A1 (zh) * 2024-04-29 2025-11-06 齐鲁制药有限公司 包含阿柏西普和其变体的组合物以及相关方法和应用
US12240888B1 (en) 2024-04-29 2025-03-04 QILU Pharmaceutical, Co., Ltd. Composition comprising aflibercept and a variant thereof, and related methods and uses
WO2025245371A1 (en) * 2024-05-22 2025-11-27 Seismic Therapeutic, Inc. Polypeptides comprising protease-resistant fc domain, compositions and uses thereof

Family Cites Families (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1522343A (en) 1923-05-02 1925-01-06 Thom Clarence Magnetic separator
US4534972A (en) 1983-03-29 1985-08-13 Miles Laboratories, Inc. Protein compositions substantially free from infectious agents
DE3871206D1 (de) * 1987-03-24 1992-06-25 Grace W R & Co Basisnaehrmedium fuer eine zellkultur.
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
US20030108545A1 (en) 1994-02-10 2003-06-12 Patricia Rockwell Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
US6811779B2 (en) * 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
WO1996006641A1 (en) * 1994-08-29 1996-03-07 Prizm Pharmaceuticals, Inc. Conjugates of vascular endothelial growth factor with targeted agents
US5721121A (en) 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
EP0953041A4 (en) 1996-08-30 2003-01-29 Life Technologies Inc SERUM-FREE CULTURAL MEDIUM FOR MAMMAL CELLS AND THEIR USE
US5804420A (en) 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
SE519827C2 (sv) 1998-03-30 2003-04-15 Viranative Ab Näringsmedium innehållande metionin samt användning av detta
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7303746B2 (en) 1999-06-08 2007-12-04 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with modified chimeric polypeptides
CA2376379C (en) 1999-06-08 2007-08-07 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US6833349B2 (en) 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
US7306799B2 (en) 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
WO2001039793A2 (en) * 1999-11-30 2001-06-07 Smithkline Beecham P.L.C. Pharmaceutical compositions containing sema7a polypeptides
DE60104282T2 (de) 2000-05-26 2005-10-13 Bristol-Myers Squibb Co. Lösliche mutante ctla4 moleküle und deren verwendung
EP1360314B1 (en) 2001-02-15 2009-01-14 Centocor, Inc. Chemically defined medium for cultured mammalian cells
WO2002083859A2 (en) 2001-04-13 2002-10-24 Wyeth Surface proteins of streptococcus pyogenes
AU2002316230A1 (en) 2001-06-13 2002-12-23 Genentech, Inc. Methods of culturing animal cells and polypeptide production in animal cells
GB0130228D0 (en) 2001-12-18 2002-02-06 Hansa Medica Ab Protein
US8777906B1 (en) 2002-01-24 2014-07-15 Robin Scott Gray Syringe with inspection window
ES2354610T5 (es) 2002-12-23 2020-09-14 Bristol Myers Squibb Co Mejora de la calidad del producto en procedimientos de cultivo de células de mamífero para la producción de proteína
US7399612B2 (en) 2003-06-30 2008-07-15 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
CN100537751C (zh) 2004-05-12 2009-09-09 华东理工大学 一种适合中国仓鼠卵巢细胞培养的无血清培养基
US7335491B2 (en) 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
AU2005302516A1 (en) 2004-10-29 2006-05-11 Centocor, Inc. Chemically defined media compositions
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
AU2006214658A1 (en) 2005-02-02 2006-08-24 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a VEGF inhibitor
CN102614134B (zh) 2005-03-25 2016-09-07 瑞泽恩制药公司 Vegf拮抗剂制剂
GB0511769D0 (en) * 2005-06-09 2005-07-20 Hansa Medical Ab Treatment
PT1901773E (pt) * 2005-06-09 2012-06-06 Hansa Medical Ab Utilização da proteinase ides (de s. pyogenes) para o tratamento de doenças e rejeição de enxertos
CN1778903A (zh) 2005-09-29 2006-05-31 华东理工大学 一种动物细胞高密度连续灌注培养方法
EP1973942B1 (en) * 2005-12-22 2011-02-09 Genentech, Inc. Recombinant production of heparin binding proteins
KR101423344B1 (ko) 2006-01-04 2014-07-30 백스터 인터내셔널 인코포레이티드 올리고펩티드-무함유 세포 배양 배지를 이용하여 단백질을 발현시키는 방법
CN100502945C (zh) 2006-03-31 2009-06-24 成都康弘生物科技有限公司 Vegf受体融合蛋白在治疗眼睛疾病中的应用
RU2432155C3 (ru) 2006-06-16 2017-11-17 Ридженерон Фармасьютикалз, Инк. Составы антагониста vegf, подходящие для интравитреального введения
DK2041270T3 (da) 2006-07-13 2014-01-27 Wyeth Llc Fremstilling af glycoproteiner
US20100267932A1 (en) * 2006-08-28 2010-10-21 Alex Eon-Duval Process for the purification of fc-fusion proteins
KR20150126730A (ko) 2006-09-10 2015-11-12 글리코토페 게엠베하 항체 발현을 위한 골수성 백혈병 기원의 인간 세포의 용도
CA2842964A1 (en) 2006-09-13 2008-03-20 Abbvie Inc. Cell culture improvements
US10259860B2 (en) 2007-02-27 2019-04-16 Aprogen Inc. Fusion proteins binding to VEGF and angiopoietin
PT2137655E (pt) 2007-04-16 2012-09-14 Momenta Pharmaceuticals Inc Produtos de glicoproteína definidos e métodos relacionados
WO2008154014A2 (en) 2007-06-11 2008-12-18 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
CN101784670A (zh) 2007-08-31 2010-07-21 弗·哈夫曼-拉罗切有限公司 糖基化谱分析
ES2388017T3 (es) * 2007-12-21 2012-10-05 Roche Glycart Ag Ensayo de estabilidad de anticuerpos
CN102112509B (zh) 2008-07-31 2013-03-20 国立大学法人京都大学 含有不饱和聚酯树脂和微纤化植物纤维的成型材料
AU2009296708A1 (en) 2008-09-26 2010-04-01 Merck Sharp & Dohme Corp. High titer antibody production
EP2435577A4 (en) 2009-05-26 2016-04-13 Momenta Pharmaceuticals Inc GLYCOPROTEIN PRODUCTION
MX368932B (es) 2009-06-26 2019-10-22 Regeneron Pharma Anticuerpos biespecificos facilmente aislados con formato de inmunoglobulina original.
WO2011014838A1 (en) 2009-07-31 2011-02-03 Baxter International Inc. Cell culture medium for adamts protein expression
RU2603055C2 (ru) * 2009-10-20 2016-11-20 Эббви Инк Выделение и очистка антител против il-13 с применением аффинной хроматографии с белком а
EP2325296A1 (en) 2009-11-20 2011-05-25 LEK Pharmaceuticals d.d. Production of glycoproteins with low N-glycolylneuraminic acid (Neu5Gc) content
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US8568250B2 (en) * 2010-07-07 2013-10-29 Nike, Inc. Golf ball with cover having zones of hardness
MX385629B (es) 2011-01-13 2025-03-18 Regeneron Pharma Uso de un antagonista de factor de crecimiento endotelial vascular para tratar trastornos oculares angiogenicos.
CN102653729B (zh) 2011-03-04 2014-07-16 上海赛金生物医药有限公司 一种用于中国仓鼠卵巢细胞的培养基
EP2697361A1 (en) 2011-04-11 2014-02-19 Cellcura Asa Protein-free culture media products for manufacturing viral-based vaccines
WO2012147048A2 (en) 2011-04-29 2012-11-01 Biocon Research Limited Methods for reducing accumulation of lactate during culturing and method for producing polypeptide
RU2580020C2 (ru) 2011-04-29 2016-04-10 Биокон Рисерч Лимитед Способ снижения гетерогенности антител и способ получения соответствующих антител
JP6055615B2 (ja) 2011-05-27 2016-12-27 アッヴィ バイオテクノロジー リミテッド Ｄａｃｈｙｐ組成物および方法
WO2013028330A2 (en) 2011-08-19 2013-02-28 Emd Millipore Corporation Methods of reducing level of one of more impurities in a sample during protein purification
WO2013054250A1 (en) * 2011-10-10 2013-04-18 Dr Reddy's Laboratories Limited Purification method
AU2012328524B2 (en) 2011-10-28 2017-05-18 Excelse Bio, Inc. Protein formulations containing amino acids
US20130281355A1 (en) 2012-04-24 2013-10-24 Genentech, Inc. Cell culture compositions and methods for polypeptide production
CN102757496B (zh) * 2012-06-07 2014-06-18 山东泉港药业有限公司 一种抗vegf抗体片段的纯化制备方法
DE202012011016U1 (de) * 2012-07-03 2012-11-28 Novartis Ag Aflibercept-Spritze
US9695416B2 (en) * 2012-07-18 2017-07-04 Siemens Healthcare Diagnostics Inc. Method of normalizing biological samples
HK1206628A1 (en) * 2012-08-02 2016-01-15 Sanofi Article of manufacture comprising aflibercept or ziv-aflibercept
EP2890782A1 (en) 2012-09-02 2015-07-08 AbbVie Inc. Methods to control protein heterogeneity
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
EP2722673B1 (en) * 2012-10-17 2017-07-12 Hexal AG Improved method of mapping glycans of glycoproteins
US9365314B2 (en) * 2012-11-16 2016-06-14 Owens-Brockway Glass Container Inc. Product and package with a photosensitive use-evident feature
US8956830B2 (en) 2013-03-14 2015-02-17 Momenta Pharmaceuticals, Inc. Methods of cell culture
US20140271622A1 (en) 2013-03-14 2014-09-18 Momenta Pharmaceuticals, Inc. Methods of cell culture
CN103146648A (zh) 2013-03-14 2013-06-12 北京京蒙高科干细胞技术有限公司 一种无动物源的淋巴细胞无血清培养基
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
PT3611180T (pt) * 2013-03-15 2022-03-15 Biomolecular Holdings Llc Imunoglobulina híbrida que contém uma ligação não peptídica
BR112015021993A8 (pt) 2013-03-15 2019-12-03 Genentech Inc polipeptídeo, métodos para sua produção, métodos para cultivo de uma célula, composição farmacêutica, kit, e meio de cultura celular
CN103773732B (zh) 2013-06-08 2016-05-11 李锋 一种化学成分确定的培养基、其应用及大规模培养哺乳动物细胞的生产工艺
WO2014204933A1 (en) 2013-06-17 2014-12-24 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
WO2015058369A1 (en) 2013-10-23 2015-04-30 Sanofi (China) Investment Co., Ltd. Use of aflibercept and docetaxel for the treatment of nasopharyngeal carcinoma
EP3102589A1 (en) 2014-02-04 2016-12-14 Biogen MA Inc. Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
CN104073464A (zh) 2014-07-08 2014-10-01 西藏天虹科技股份有限责任公司 一种cho细胞无血清培养基及其制备方法
AR101262A1 (es) 2014-07-26 2016-12-07 Regeneron Pharma Plataforma de purificación para anticuerpos biespecíficos
GB201502306D0 (en) * 2015-02-12 2015-04-01 Hansa Medical Ab Protein
GB201502305D0 (en) * 2015-02-12 2015-04-01 Hansa Medical Ab Protein
KR20240093725A (ko) * 2015-03-12 2024-06-24 메디뮨 엘엘씨 알부민 융합 단백질의 정제 방법
KR101867134B1 (ko) * 2015-03-23 2018-06-12 한양대학교 산학협력단 포유류 세포를 이용하여 목적 물질을 고효율로 생산하기 위한 세포 배양 배지, 이를 이용한 세포 배양 방법 및 목적 물질의 생산 방법
AU2016239662B2 (en) 2015-04-01 2021-12-16 Boehringer Ingelheim International Gmbh Cell culture medium
CN105002242A (zh) 2015-07-23 2015-10-28 苏州康聚生物科技有限公司 用于cho细胞中高效表达重组人促甲状腺激素的无血清培养基及其应用
TW202440903A (zh) * 2015-08-04 2024-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法（一）
ES2913530T3 (es) 2015-08-12 2022-06-02 Novartis Ag Métodos para tratar trastornos oftálmicos
WO2017069158A1 (ja) * 2015-10-22 2017-04-27 プロテノバ株式会社 イムノグロブリン結合ポリペプチド
EP3377151A1 (en) 2015-11-18 2018-09-26 Formycon AG Pre-filled plastic syringe containing a vegf antagonist
WO2017087798A1 (en) * 2015-11-18 2017-05-26 Formycon Ag Pre-filled pharmaceutical package comprising a liquid formulation of a vegf-antagonist
CN105368808B (zh) * 2015-11-30 2019-04-30 苏州康聚生物科技有限公司 一种IdeS蛋白酶、其制备方法及应用
US20170174781A1 (en) 2015-12-22 2017-06-22 Regeneron Pharmaceuticals, Inc. Bispecific Anti-CD20/Anti-CD3 Antibodies to Treat Acute Lymphoblastic Leukemia
HRP20231156T1 (hr) 2015-12-22 2024-01-05 Regeneron Pharmaceuticals, Inc. Kombinacija anti-pd-1 antitijela i bispecifičnih anti-cd20/anti-cd3 antitijela za liječenje raka
EP3196646B1 (en) * 2016-01-19 2019-12-18 Hexal AG Methods of mapping protein variants
EP3407868A1 (en) 2016-01-26 2018-12-05 Formycon AG Liquid formulation of a vegf antagonist
CN107025553A (zh) * 2016-01-29 2017-08-08 上海新卡说信息技术有限公司 一种交易处理方法以及交易系统
US20200283472A1 (en) * 2016-03-29 2020-09-10 Navya Biologicals Pvt. Ltd A process for purification of fc-fusion proteins
KR101685532B1 (ko) * 2016-04-26 2016-12-13 한국프라임제약주식회사 혈관내피성장인자 수용체 융합단백질
CN106279412A (zh) * 2016-09-12 2017-01-04 广东东阳光药业有限公司 一种抗vegf类单克隆抗体的纯化方法
RS63660B1 (sr) 2016-09-23 2022-11-30 Regeneron Pharma Anti-muc16 (mucin 16) antitela
MA46417A (fr) 2016-09-23 2019-07-31 Regeneron Pharma Anticorps anti-steap2, conjugués anticorps-médicament, et molécules bispécifiques de liaison à l'antigène qui se lient à steap2 et cd3, et leurs utilisations
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
EP3541365A1 (en) * 2016-11-21 2019-09-25 Just Biotherapeutics, Inc. Aflibercept formulations and uses thereof
DK3559027T3 (da) * 2016-12-23 2022-09-05 Serum Institute Of India Pvt Ltd Fremgangsmåder til forbedring af antistofoproduktivitet i pattedyrecellekultur og minimering af aggregering nedstrøms, formuleringsprocesser og stabile antistofformuleringer opnået deraf
US11266745B2 (en) 2017-02-08 2022-03-08 Imaginab, Inc. Extension sequences for diabodies
US10941178B2 (en) * 2017-03-17 2021-03-09 Gilead Sciences, Inc. Method of purifying an antibody
KR101861163B1 (ko) 2017-04-26 2018-05-25 삼천당제약주식회사 안과용 약학 조성물
WO2018215580A1 (en) * 2017-05-24 2018-11-29 Formycon Ag Method for sterilizing prefilled plastic syringes containing a vegf antagonist
US20210228738A1 (en) 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
EP3668985B1 (en) * 2017-08-17 2021-06-16 Just-Evotec Biologics, Inc. Method of purifying glycosylated protein from host cell galectins and other contaminants
EP3697449A1 (en) * 2017-10-18 2020-08-26 REGENXBIO Inc. Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified vegf-trap
CN111356471A (zh) * 2017-11-20 2020-06-30 济世发展生物药业有限公司 包含赖氨酸盐作为张力调节剂的阿柏西普制剂及其用途
CN109929027B (zh) * 2017-12-15 2020-10-09 山东博安生物技术有限公司 采用线性洗脱步骤的重组融合蛋白纯化方法
CN109929038B (zh) * 2017-12-15 2020-10-09 山东博安生物技术有限公司 Vegf捕获剂融合蛋白的纯化方法
US11426446B2 (en) 2018-03-08 2022-08-30 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
WO2019173767A1 (en) * 2018-03-08 2019-09-12 Coherus Biosciences Inc. Stable aqueous formulations of aflibercept
EP4321870B1 (en) 2018-03-13 2025-07-30 Amgen Inc. Methods for the preparation of trypsin-resistant polypeptides for mass spectrometric analysis
KR20210021299A (ko) 2018-05-10 2021-02-25 리제너론 파아마슈티컬스, 인크. 고농도 vegf 수용체 융합 단백질 함유 제제
EP3876320A4 (en) * 2018-10-29 2022-12-14 China Petroleum & Chemical Corporation POROUS COMPOSITE FOR GENERATION OF AN ELECTRIC ARC IN A MICROWAVE FIELD, METHOD OF ITS MANUFACTURE AND ITS USE
WO2020102740A2 (en) * 2018-11-16 2020-05-22 Spark Therapeutics, Inc. Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
AU2020216368B2 (en) 2019-01-30 2025-04-24 Amgen Inc. Aflibercept attributes and methods of characterizing and modifying thereof
WO2020229584A1 (en) 2019-05-16 2020-11-19 Formycon Ag Method for reducing methionine oxidation in recombinant proteins
KR102286892B1 (ko) * 2019-07-08 2021-08-06 삼천당제약주식회사 안과용 단백질 제제의 정제방법
KR20230152810A (ko) * 2019-12-06 2023-11-03 리제너론 파아마슈티컬스, 인크. 항-vegf 단백질 조성물 및 이를 생산하는 방법

Also Published As

Publication number Publication date
IL288357A (en) 2022-01-01
IL296512A (en) 2022-11-01
IL301888B1 (en) 2024-11-01
US12319728B2 (en) 2025-06-03
IL318471A (en) 2025-03-01
AU2020398125A1 (en) 2021-10-28
AU2023201590B2 (en) 2025-07-03
US20230357357A1 (en) 2023-11-09
US20210171570A1 (en) 2021-06-10
KR20240005206A (ko) 2024-01-11
US11407813B2 (en) 2022-08-09
UA129709C2 (uk) 2025-07-09
US11306135B2 (en) 2022-04-19
EP4524237A2 (en) 2025-03-19
JP2024119936A (ja) 2024-09-03
NZ781143A (en) 2023-05-26
IL288351B1 (en) 2024-01-01
AU2020398547C1 (en) 2023-05-11
ZA202107646B (en) 2022-03-30
TW202128743A (zh) 2021-08-01
US20230272044A1 (en) 2023-08-31
US20220033472A1 (en) 2022-02-03
KR20220038062A (ko) 2022-03-25
IL296863B1 (en) 2023-06-01
JP2022548197A (ja) 2022-11-17
US11098311B2 (en) 2021-08-24
US20220033471A1 (en) 2022-02-03
US11459373B2 (en) 2022-10-04
US20230119662A1 (en) 2023-04-20
AU2020398830A1 (en) 2021-10-28
EP4524148A3 (en) 2025-07-23
IL288367B2 (en) 2023-02-01
US20210171605A1 (en) 2021-06-10
IL296512B2 (en) 2023-12-01
IL309491B1 (en) 2025-02-01
IL317707A (en) 2025-02-01
US11485770B2 (en) 2022-11-01
US20250289868A1 (en) 2025-09-18
NZ781145A (en) 2023-05-26
MX2022006760A (es) 2023-01-30
AU2023201590A1 (en) 2023-04-13
EP4516800A3 (en) 2025-07-09
IL309491A (en) 2024-02-01
US20210371501A1 (en) 2021-12-02
MY190626A (en) 2022-04-27
AU2023201586B2 (en) 2025-08-28
WO2021112924A1 (en) 2021-06-10
AU2025263786A1 (en) 2025-11-27
US20210214733A1 (en) 2021-07-15
MX2023005421A (es) 2023-05-23
IL288360B2 (en) 2023-09-01
AU2023201589B2 (en) 2025-08-28
IL296893B2 (en) 2024-05-01
US20240309064A1 (en) 2024-09-19
ZA202107647B (en) 2022-03-30
AU2020396490C1 (en) 2023-04-27
JP2025114741A (ja) 2025-08-05
US11053280B2 (en) 2021-07-06
US20220098280A1 (en) 2022-03-31
BR112021025359A2 (pt) 2022-06-21
CO2021018214A2 (es) 2022-01-17
US11548932B2 (en) 2023-01-10
CO2021018181A2 (es) 2022-01-17
TW202128744A (zh) 2021-08-01
US20210214430A1 (en) 2021-07-15
EP3931303A1 (en) 2022-01-05
IL288357B2 (en) 2023-03-01
JP2022547652A (ja) 2022-11-15
AU2023201588B2 (en) 2025-06-26
CO2022000660A2 (es) 2022-01-28
EP3906249A1 (en) 2021-11-10
IL302921B1 (en) 2025-05-01
IL296864B1 (en) 2023-06-01
US20210206833A1 (en) 2021-07-08
IL288352B2 (en) 2023-03-01
IL288352A (en) 2022-01-01
AU2023201748A1 (en) 2023-06-01
BR112021025769A2 (pt) 2022-04-12
AU2020397803B2 (en) 2022-12-15
US12054532B2 (en) 2024-08-06
US20220396608A1 (en) 2022-12-15
KR20230051296A (ko) 2023-04-17
US11186625B2 (en) 2021-11-30
AU2020398125B2 (en) 2022-12-15
MX2022011973A (es) 2022-11-09
AU2020397803C1 (en) 2023-05-11
US11535663B2 (en) 2022-12-27
MX2023014077A (es) 2023-12-11
WO2021112928A1 (en) 2021-06-10
BR112021025438A2 (pt) 2022-06-21
MY190686A (en) 2022-05-10
US20220009997A1 (en) 2022-01-13
SG11202110955VA (en) 2021-10-28
EP4516800A2 (en) 2025-03-05
MX2022006758A (es) 2023-01-30
PE20221770A1 (es) 2022-11-11
TWI867028B (zh) 2024-12-21
KR20250053206A (ko) 2025-04-21
US20250197474A1 (en) 2025-06-19
KR20220038349A (ko) 2022-03-28
KR102519234B1 (ko) 2023-04-10
CA3159586A1 (en) 2021-06-10
NZ781142A (en) 2023-05-26
TW202134256A (zh) 2021-09-16
PE20221788A1 (es) 2022-11-25
KR102860764B1 (ko) 2025-09-19
KR20230152810A (ko) 2023-11-03
NZ781137A (en) 2023-05-26
JP7681079B2 (ja) 2025-05-21
JP7744391B2 (ja) 2025-09-25
CN114423783A (zh) 2022-04-29
TW202128745A (zh) 2021-08-01
SG11202110972UA (en) 2021-10-28
US11104715B2 (en) 2021-08-31
US12012445B2 (en) 2024-06-18
CN114206925A (zh) 2022-03-18
EP4524236A3 (en) 2025-07-23
JP2023179531A (ja) 2023-12-19
AU2020397865B2 (en) 2022-12-15
CN114206907A (zh) 2022-03-18
EP4524147A3 (en) 2025-07-23
US20220227836A1 (en) 2022-07-21
TW202521150A (zh) 2025-06-01
TW202122417A (zh) 2021-06-16
US20230331812A1 (en) 2023-10-19
BR112021025432A2 (pt) 2022-06-21
US20230068199A1 (en) 2023-03-02
JP2022550930A (ja) 2022-12-06
US20220275054A1 (en) 2022-09-01
WO2021112926A1 (en) 2021-06-10
KR20220038348A (ko) 2022-03-28
PE20221789A1 (es) 2022-11-25
US20250034231A1 (en) 2025-01-30
ZA202308519B (en) 2025-11-26
WO2021112927A1 (en) 2021-06-10
IL288367A (en) 2022-01-01
US12012444B2 (en) 2024-06-18
JP2023171771A (ja) 2023-12-05
EP4524148A2 (en) 2025-03-19
JP2022548818A (ja) 2022-11-22
AU2020397803A1 (en) 2021-10-28
AU2023201748B2 (en) 2025-08-21
MY193354A (en) 2022-10-06
US20240067701A1 (en) 2024-02-29
IL288355A (en) 2022-01-01
WO2021112929A1 (en) 2021-06-10
MY190625A (en) 2022-04-27
AU2020398830C1 (en) 2023-04-27
MY190624A (en) 2022-04-27
IL288357B (en) 2022-11-01
EP3906302A1 (en) 2021-11-10
CN114206924A (zh) 2022-03-18
MY190627A (en) 2022-04-27
US11753459B2 (en) 2023-09-12
US12202883B2 (en) 2025-01-21
US20210284684A1 (en) 2021-09-16
MY190623A (en) 2022-04-27
MX2021014862A (es) 2022-09-27
CN114401994A (zh) 2022-04-26
US11286290B2 (en) 2022-03-29
SG11202110964QA (en) 2021-10-28
MX2021014863A (es) 2022-09-28
CA3129193A1 (en) 2021-06-10
AU2023201588A1 (en) 2023-04-13
US20240317835A1 (en) 2024-09-26
US20220162289A1 (en) 2022-05-26
US11958894B2 (en) 2024-04-16
IL301888B2 (en) 2025-03-01
IL309491B2 (en) 2025-06-01
EP3931204A1 (en) 2022-01-05
AU2023201585B2 (en) 2025-08-14
US20220227835A1 (en) 2022-07-21
IL304390A (en) 2023-09-01
IL309560B2 (en) 2025-05-01
IL288367B (en) 2022-10-01
AU2020397865A1 (en) 2021-10-28
US11174283B2 (en) 2021-11-16
KR20220041083A (ko) 2022-03-31
MY193349A (en) 2022-10-06
US12049489B2 (en) 2024-07-30
US12338274B2 (en) 2025-06-24
MY193355A (en) 2022-10-06
KR20220038347A (ko) 2022-03-28
MX2022012042A (es) 2022-10-27
BR112022001016A2 (pt) 2022-08-16
IL309560B1 (en) 2025-01-01
JP2024009949A (ja) 2024-01-23
JP2024167326A (ja) 2024-12-03
KR102619866B1 (ko) 2024-01-04
IL296863A (en) 2022-11-01
IL288355B2 (en) 2023-03-01
IL296864A (en) 2022-11-01
IL296893A (en) 2022-12-01
US20230235019A1 (en) 2023-07-27
AU2023201586A1 (en) 2023-04-13
EP3906250A1 (en) 2021-11-10
US11649273B2 (en) 2023-05-16
IL304390B2 (en) 2025-05-01
JP2022547651A (ja) 2022-11-15
US20230041349A1 (en) 2023-02-09
US12077570B2 (en) 2024-09-03
AU2020397865C1 (en) 2023-04-27
US20220009999A1 (en) 2022-01-13
IL302538B2 (en) 2025-06-01
IL302538B1 (en) 2025-02-01
US11732025B2 (en) 2023-08-22
IL309560A (en) 2024-02-01
MY193353A (en) 2022-10-06
IL288360B1 (en) 2023-05-01
AU2020396490B2 (en) 2022-12-15
NZ781138A (en) 2023-05-26
US20220389081A1 (en) 2022-12-08
ZA202107644B (en) 2022-03-30
US11505593B2 (en) 2022-11-22
IL304390B1 (en) 2025-01-01
US11098112B2 (en) 2021-08-24
MX2022006788A (es) 2022-07-11
JP2024009950A (ja) 2024-01-23
AU2020398547A1 (en) 2021-10-28
IL288351B2 (en) 2024-05-01
PE20221791A1 (es) 2022-11-25
US20210206832A1 (en) 2021-07-08
US11180540B2 (en) 2021-11-23
CO2021018234A2 (es) 2022-01-17
IL296512B1 (en) 2023-08-01
IL296863B2 (en) 2023-10-01
TW202128991A (zh) 2021-08-01
ZA202208710B (en) 2024-09-25
CA3129193C (en) 2022-10-04
NZ781136A (en) 2023-05-26
US11299532B2 (en) 2022-04-12
US11505594B2 (en) 2022-11-22
IL296864B2 (en) 2023-10-01
US11459374B2 (en) 2022-10-04
KR102519236B1 (ko) 2023-04-10
SG11202110968VA (en) 2021-10-28
US20220009998A1 (en) 2022-01-13
AU2023201585A1 (en) 2023-04-13
IL296893B1 (en) 2024-01-01
CA3172625A1 (en) 2021-06-10
EP3906303A1 (en) 2021-11-10
SG11202110958QA (en) 2021-10-28
JP2024026116A (ja) 2024-02-28
TW202521567A (zh) 2025-06-01
US20220235116A1 (en) 2022-07-28
AU2025242105A1 (en) 2025-10-23
IL288360A (en) 2022-01-01
EP4524147A2 (en) 2025-03-19
KR20240005222A (ko) 2024-01-11
JP7673311B2 (ja) 2025-05-08
PE20221261A1 (es) 2022-08-16
US20240294606A1 (en) 2024-09-05
CA3172631C (en) 2024-01-02
AU2020396490A1 (en) 2021-10-28
CA3172631A1 (en) 2021-06-10
AU2020398830B2 (en) 2022-12-15
CO2021018192A2 (es) 2022-01-17
US11542317B1 (en) 2023-01-03
AU2020398125C1 (en) 2023-05-11
SG11202110953UA (en) 2021-10-28
KR20220035393A (ko) 2022-03-22
US11440950B2 (en) 2022-09-13
US11472861B2 (en) 2022-10-18
TW202525842A (zh) 2025-07-01
IL288351A (en) 2022-01-01
EP4524237A3 (en) 2025-07-09
US12054533B2 (en) 2024-08-06
IL302538A (en) 2023-07-01
IL288352B (en) 2022-11-01
EP4524236A2 (en) 2025-03-19
WO2021112923A1 (en) 2021-06-10
AU2023201589A1 (en) 2023-04-06
MY193350A (en) 2022-10-06
WO2021112925A1 (en) 2021-06-10
IL302921A (en) 2023-07-01
CO2021018203A2 (es) 2022-01-17
JP2022552052A (ja) 2022-12-15
IL302921B2 (en) 2025-09-01
IL301888A (en) 2023-06-01
US20220127331A1 (en) 2022-04-28
AU2020398547B2 (en) 2022-12-22
CN114206914A (zh) 2022-03-18
MX2022006759A (es) 2023-01-30
IL288355B (en) 2022-11-01
BR112021025158A2 (pt) 2022-06-21
KR20230051297A (ko) 2023-04-17
KR20240007293A (ko) 2024-01-16
US20220048975A1 (en) 2022-02-17
TW202509053A (zh) 2025-03-01
TWI865587B (zh) 2024-12-11
MY193351A (en) 2022-10-06

Similar Documents

Publication Publication Date Title
PE20221790A1 (es) Composiciones de proteina anti-vegf y metodos para producir la misma
EP4295911A2 (en) Humanized anti-complement factor c1q antibodies and uses thereof
AR106752A1 (es) Proteínas de unión a pd1 / ctla4
MX2022005777A (es) Etiquetado utilizando transposomas inmovilizados con ligadores.
NZ581418A (en) Novel rabbit antibody humanization methods and humanized rabbit antibodies
NO20090424L (no) Humane antistoffer mot ErbB2
EP2599873A3 (en) Plants having enhanced yield-related traits and a method for making the same
EP4575499A3 (en) Stepwise sequencing by non-labeled reversible terminators or natural nucleotides
WO2008058282A3 (en) Methods and compositions for large-scale analysis of nucleic acids using dna deletions
WO2009120927A3 (en) Methods of treatment
EA201170947A1 (ru) Растения, имеющие улучшенные характеристики урожайности, и способ их получения
RU2018119366A (ru) Мыши с гуманизированной легкой цепью
WO2010045115A3 (en) Treating subsurface hydrocarbon containing formations and the systems, methods, and processes utilized
WO2009056566A3 (en) Plants having enhanced yield-related traits and a method for making the same
MX359738B (es) Metodos de seleccion.
WO2015119941A3 (en) Genome fractioning
EP3564259A3 (en) Recognition tags for tgase-mediated conjugation
ATE516368T1 (de) Erstellung eines echtzeit-genexpressionsprofils
DK1869186T3 (da) Fremgangsmåde og midler til fjernelse af en udvalgt sekvens
HK1250038A1 (zh) 选择结合抗原的轻链可变区的非人动物
WO2007041171A3 (en) Method of identifying membrane lg specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells
EA201170752A1 (ru) Растения с повышенной устойчивостью к абиотическому стрессу и/или улучшенными характеристиками урожайности и способ их получения
JP2016533758A5 (es)
HRP20171641T1 (hr) Genetički polimorfizam kod makularne degeneracije vezane uz dob
WO2007027805A3 (en) Method for generating anti-variable region monoclonal antibodies